Showing results (231-240 of 299) with videos related to
Sort By:
Pageof 30
Pathogens & Immunity|March 20, 2024
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?Justin Harper, Michael R Betts, Mathias Lichterfeld, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter StudiesRodolphe Thiébaut, Ana Jarne, Jean-Pierre Routy, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)Robert S Wallis, Robert Kalayjian, Jeffrey M Jacobson, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 19, 2003
Role of Baseline pol Genotype in HIV-1 Fitness EvolutionJan Weber, Hector R Rangel, Bikram Chakraborty, et al.The Journal of Infectious Diseases|April 24, 2014
Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infectionPeter W Hunt, Elizabeth Sinclair, Benigno Rodriguez, et al.Science Translational Medicine|July 12, 2013
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolismIvan Vujkovic-Cvijin, Richard M Dunham, Shoko Iwai, et al.Plos One|May 16, 2019
HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumoniaRichard J Wang, Julia Moore, Daniela Moisi, et al.The Journal of Infectious Diseases|October 5, 2010
Determinants of protection among HIV‐exposed seronegative persons: an overviewMichael M Lederman, Galit Alter, Demetre C Daskalakis, et al.JAMA|September 28, 2006
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infectionBenigno Rodríguez, Ajay K Sethi, Vinay K Cheruvu, et al.Archives of Internal Medicine|March 29, 2007
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, et al.Pageof 30